Friday, November 22, 2019

// // Leave a Comment

Major trial backs immunotherapy as standard first-line treatment for head and neck cancer

Immunotherapy is better than standard 'extreme' chemotherapy as first-line treatment for advanced head and neck cancer and can keep some patients alive for more than three years, a major new trial reports. The immunotherapy drug pembrolizumab alone ...

from Google Alert - health https://ift.tt/2QIGdHj
via IFTTT

0 comments:

Post a Comment